Merck Kgaa news from FiercePharma
NewsDaiichi takes 130 reps off Merck KgAA's hands
SPOTLIGHT: Daiichi takes 130 reps off German Merck's handsMore evidence that pharma sales is fraught with change: Daiichi Sankyo's German unit has agreed to take over most of Merck KGaA's primary Read more...
Indians ask Ranbaxy CEO who's next
In the investment world, the proposed Daiichi Sankyo-Ranbaxy Laboratories merger is just another big deal. But in India, it's taken on symbolic significance. The family-controlled company Read more...
Erbitux, KRAS gene star at ASCO
As expected, headlines have been spewing from the American Society of Clinical Oncology meeting like ash from a volcano. And as promised, we bring you a roundup of the latest and greatest on using Read more...
ASCO already churning out news
Today marks the start of the annual American Society of Clinical Oncology meeting, always a big news generator in the pharma biz. We'll let our sister pub FierceBiotech keep you up to date on the Read more...
ALSO NOTED: Novartis cuts malaria drug price; India bars Cipla from exporting Tarceva copy;
> Novartis is slashing the public-sector price of its antimalarial med Coartem by 20 percent, to 80 cents from $1, to make the treatment more widely available. Read more...
Stanley: Erbitux outperformed Avastin
Morgan Stanley got a juicy scoop on the Avastin versus Erbitux boxing match: Genentech's Avastin faces news that as-yet-unpublished data shows Erbitux delivering an "unexpected survival Read more...
ALSO NOTED: Merck KGaA has money for deals; Alcon gets FDA OK for hay fever spray;
> Merck KGaA is pursuing acquisitions and licensing deals to shore up growth and has the funding ready to finance any transactions, CEO Karl-Ludwig Kley said. Read more...
ALSO NOTED: U.S. R&D headcount tumbles in key categories; Paion to buy troubled CeNes;
> Pharmalot has been crunching the numbers for R&D jobs and concludes that the U.S. is seeing a considerable amount of shrinkage in the field. Read more...
ALSO NOTED: German Merck wants to make pharma buys; Novartis breast-cancer med prevents recurrence;
> Merck KGaA is on the prowl for pharma acquisitions, CEO Ludwig Kley told a German newspaper. Report > Read more...
ALSO NOTED: Jarvik takes fourth in ad ranking;Glaxo slashes AIDS drug costs for poor;
> Which TV drug ads lodged most securely in consumers' brains? That ubiquitous Nasonex bee hit No. Read more...
| Press ReleasesPRESS RELEASE: Merck Initiates a New Phase III Clinical Trial of Safinamide in Early Parkinson’s Disease Merck Initiates a New Phase III Clinical Trial of Safinamide in Early Parkinson’s Disease MOTION-Trial Will Evaluate Safety and Efficacy of Two Doses of Safinamide (50 and 100 mg once daily) as Read more... PRESS RELEASE: ImClone and BMS Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan ImClone Systems and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan NEW YORK, Oct. 17 -- ImClone Systems Incorporated and Read more... PRESS RELEASE: Gene Logic Establishes Agreement with Merck Serono Gene Logic Establishes Agreement with Merck Serono to Discover New Development Paths for Multiple Clinical-Stage Drug Candidates GAITHERSBURG, Md. -- Aug 23, 2007 - Gene Logic Inc. Read more... |
Get more Merck Kgaa coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets